| Literature DB >> 35631264 |
Madlen Ungersboeck1, Xiaowen Tang1, Vanessa Neeff1, Dominic Steele1, Pascal Grimm1, Matthew Fenech1.
Abstract
The recommended first-line therapy in type 2 diabetes (T2D) is lifestyle modification. In many patients, such interventions fail, and disease progresses inexorably to medication requirement. A potential reason for the failure of standard nutritional interventions is the use of generic dietary advice, with no personalisation to account for differences in the effect of food on blood glucose between different individuals. Another is the lack of instant feedback on the impact of dietary modification on glycaemic control, which supports sustained behaviour change. The use of continuous glucose monitoring (CGM) may help address both these shortcomings. We conducted an observational study to explore how personalised nutritional information impacts glycaemic control and patient-reported outcome measures (PROMs) of well-being. Free-living people with T2D eating their normal diet were provided with personalised nutritional recommendations by state-registered nutritionists based on the CGM-enabled analysis of individual post-prandial glycaemic responses (PPGRs). Participants demonstrated considerable inter-individual differences in PPGRs, reductions in post-prandial incremental area under the curve (iAUC) and daytime AUC, and improvements in energy levels, ability to concentrate, and other PROMs. These results suggest a role for personalised nutritional recommendations based on individual-level understanding of PPGRs in the non-pharmaceutical management of T2D.Entities:
Keywords: continuous glucose monitoring; digital tools; personalised nutrition; type 2 diabetes
Mesh:
Substances:
Year: 2022 PMID: 35631264 PMCID: PMC9145975 DOI: 10.3390/nu14102123
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Eligibility criteria.
| Inclusion | Exclusion |
|---|---|
| Diagnosis of type 2 diabetes | Pregnancy or breastfeeding |
| Age ≥ 18 years | Treated with insulin, sulphonylureas, glinides |
| Own and are able to operate a smartphone | Unable to consent to involvement in research |
| Episodes of symptomatic hypoglycaemia in the last 3 months |
Demographic characteristics of eligible participants.
| Demographics | Count | Descriptive Statistics |
|---|---|---|
| Age | ||
| <30 to 40 | 3 (12.50%) | |
| 41 to 50 | 7 (29.17%) | |
| 51 to 60 | 7 (29.17%) | |
| 61 to 70 | 5 (20.83%) | |
| 71 to 80 | 2 (8.33%) | |
| Mean ± SD | 54 ± 11.18 years | |
| Maximum | 74 years | |
| Minimum | 27 years | |
|
| ||
| Female | 18 (75.00%) | |
| Male | 6 (25.00%) | |
|
| ||
| <6.5% | 2 (8.33%) | |
| 6.5% to 6.9% | 6 (25.00%) | |
| 7% to 7.9% | 6 (25.00%) | |
| 8% to 8.9% | 5 (20.83%) | |
| 9% to 10% | 3 (12.50%) | |
| >10% | 2 (8.33%) | |
| Mean ± SD | 7.92 ± 1.77% | |
| Maximum | 13.40% | |
| Minimum | 5.30% | |
|
| ||
| Mean ± SD | 95.78 ± 17.61 kg | |
| Maximum | 125.40 kg | |
| Minimum | 61 kg | |
|
| ||
| Mean ± SD | 31.87 ± 6.27 kg/m2 | |
| Maximum | 44.43 kg/m2 | |
| Minimum | 21.36 kg/m2 | |
| Median | 31.59 kg/m2 | |
|
| ||
| <2000 | 1 (4.17%) | |
| 2000 to 2009 | 3 (12.50%) | |
| 2010 to 2019 | 12 (50.00%) | |
| >2020 | 8 (33.33%) | |
| Mean ± SD | 2015 ± 8 years | |
| Maximum | 2021 | |
| Minimum | 1986 | |
|
| ||
| <31 | 3 (12.50%) | |
| 31 to 40 | 1 (4.17%) | |
| 41 to 50 | 11 (45.83%) | |
| 51 to 60 | 6 (25.00%) | |
| 61 to 70 | 3 (12.50%) | |
| Mean ± SD | 47 ± 11.81 years | |
| Maximum | 68 years | |
| Minimum | 17 years | |
|
| ||
| No | 3 (11.54%) | |
| Yes | 21 (88.46%) | |
| 1 type of AM | 9 (37.50%) | |
| >1 type of AM | 12 (50.00%) | |
| metformin | 19 (79.17%) | |
| GLP-1-agonist 1 | 4 (16.67%) | |
| SGLT-2-inhibitor 1 | 6 (25.00%) | |
| DPP-4 1 | 7 (29.17%) | |
| Alpha-glucosidase inhibitors | 1 (4.17%) | |
|
| ||
| No | 9 (37.50%) | |
| Yes | 15 (62.50%) | |
| Hypertension | 8 (33.33%) | |
| Autoimmune disease | 3 (12.50%) | |
| Other illness 1 | 9 (37.50%) |
1 AM, antidiabetes medication; BMI, body mass index; DPP-4, dipeptidylpeptidase4; GLP-1, glucagon-like peptide-1 receptor; HbA1c, haemoglobin A1c; SD, standard deviation; SGLT-2, sodium glucose cotransporter-2; other illnesses included rheumatoid arthritis, liver cirrhosis, hypercholesterolaemia, hypertriglyceridaemia, and lymphoedema.
Figure 1Identification of individual differences. Heatmap of regression coefficient from multivariate regression analysis on 24 patients, all of whom had at least 28 meals annotated with nutrition values. The number of stars (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001) represent significance of the linear relationship between nutrient and maximal glucose level (gmax). The value of the regression coefficient (colour) represents the strength of the positive/negative correlation between each nutrient and gmax. A red colour indicates that the increase in glucose level is more pronounced if the amount of the relevant macronutrient increases in the meal when controlling for the amount of other macronutrients.
Figure 2Glycaemic metrics pre- and post-insight phase. (a) The median incremental area under the curve (iAUC). (b) Daytime area under the curve (AUCd). (c) Mean glucose levels. (d) Percentage (%) of time spent in hyperglycaemia. (e) Summary statistics for (a–d) including relative difference (%), absolute difference, and p value. * For all metrics, mean ± SD is shown, except for median iAUC, for which median ± IQR is shown. (a–d) Each dot represents one individual participant. Wilcoxon matched-pair signed ranked test was chosen to test for significance; error bars show median ± IQR; n = 24.
Multiple linear regression analysis of baseline characteristics and glycaemic metrics.
| Major Baseline Characteristics | Regression | Standard Error of | |
|---|---|---|---|
| Pre-insight median iAUC | |||
| Age | 5.566 | 0.836 | 0.836 |
| HbA1c | 118.845 | 0.437 | 0.437 |
| BMI | −17.832 | 0.697 | 0.697 |
| Other diseases | 68.698 | 0.903 | 0.903 |
|
| |||
| Age | 1.822 | 0.950 | 0.950 |
| HbA1c | −36.546 | 0.824 | 0.824 |
| BMI | 6.180 | 0.901 | 0.901 |
| Other diseases | −174.313 | 0.775 | 0.775 |
|
| |||
| Age | −3.744 | 0.884 | 0.884 |
| HbA1c | −155.391 | 0.289 | 0.289 |
| BMI | 24.012 | 0.583 | 0.583 |
| Other diseases | −243.010 | 0.651 | 0.651 |
Figure 3Participant-reported outcome measures. Self-reported energy levels, anxiety around increased blood glucose, feelings of satiety, and difficulty in concentration were measured weekly over the course of the programme. (a) Percentage (%) of participants agreeing or strongly agreeing with the statement are shown. Percentages (%) depicted directly in the line-dot graph describe the relative weekly difference compared to baseline questionnaire. (b) Panel OLS fixed-effect model regression analysis outcomes including estimated parameter, p-values, and standard error for each question is shown. Time was used as the independent variable (Y) and the question as the dependent variable (X) for the within-individual effects, and the standard error was clustered for one person. Data were tested for normal distribution.
Coding frame and example codes as a result of the thematic analysis conducted on 6 user interviews.
| Themes | User Quotes |
|---|---|
| The perceived impact of knowledge gained by CGM | |
| Altered meal planning behaviour | The bad meals, so to say, don’t make it on my grocery list. (U4) |
| Recycling of good ingredients for other meals | I looked at what was positive and then I also looked at which building blocks I could use or could use later and perhaps modify them a little and then make another meal out of it that would have the same positive effect. (U3) |
| Decreasing proportions of less ideal ingredients | Or take one tablespoon or two tablespoons less oatmeal. Well, you’ll still be full with the nuts you add and everything. But take a little less of it. And I found that really very, very pleasant to be able to observe over these four weeks that there had been a clear improvement. (U5) |
| Reduction in hidden sugars | But I eat much, much more consciously. I always try to include nuts and things like that, things that have value, and I really refrain from anything that basically also contains hidden sugars and things like that. I stick to that consistently. (U6) |
| Increased motivation | I was somehow relieved. I didn’t do everything wrong. Before I really thought I was doing everything wrong when it was so high. And yes, I’m highly motivated, totally motivated. (U2) |
|
| |
| Meal analysis of meal components | But you suddenly notice it, or at least I do, much more consciously, because otherwise you don’t dissect and pick apart your meal like that. (U5) |
| Personalised meal analysis and recommendations | With so many programmes, I would say, or dietary change programmes, a lot of things are given to you and you have to integrate things that you might not like so much. They also include foods that you don’t use in your routine. And I actually found it very, very good that I got information about the value of my diet tailored to my meal plan, to my family’s daily routine. (U1) |
| Combination of CGM curve and meal logging | But I can also link that [CGM values] to the meal. That I can then see okay, I ate this and that and afterwards it rises and falls again in that specific period of time. This is also possible in the morning or at lunchtime with every meal, so that it is easier to follow up than if I were to take a blood sample. (U3) |
|
| |
| Weight reduction | If I want to lose weight, I also have to pay a bit of attention to how these macronutrients are and what influence they have. So in this case, not only for blood sugar, but also overall. (U3) |
| Lifestyle barriers | Testing the meals, that is actually something that I find very interesting. And actually, I would have liked to do all of them, but that is quite difficult for me in my everyday life. Because I can’t eat or drink anything else for two hours before and two hours after the meal. (U1) * |
* The user referred to the time span of 2 h required between two meals to calculate reliable meal analysis results [26].